JP2019505594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505594A5 JP2019505594A5 JP2018562701A JP2018562701A JP2019505594A5 JP 2019505594 A5 JP2019505594 A5 JP 2019505594A5 JP 2018562701 A JP2018562701 A JP 2018562701A JP 2018562701 A JP2018562701 A JP 2018562701A JP 2019505594 A5 JP2019505594 A5 JP 2019505594A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pyridin
- methylmorpholin
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 239000000460 chlorine Substances 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- -1 —NHSO 2 R 9 Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- WKIRDESWGLBYSE-UHFFFAOYSA-N 4-(3-methylmorpholin-4-yl)-6-(2-phenylphenyl)-1H-pyridin-2-one Chemical compound CC1N(CCOC1)C1=CC(NC(=C1)C1=C(C=CC=C1)C1=CC=CC=C1)=O WKIRDESWGLBYSE-UHFFFAOYSA-N 0.000 claims 1
- LYBKZXJPARFTAV-UHFFFAOYSA-N 4-(3-methylmorpholin-4-yl)-6-(4-methylpyridin-3-yl)-1H-pyridin-2-one Chemical compound CC1N(CCOC1)C1=CC(NC(=C1)C=1C=NC=CC=1C)=O LYBKZXJPARFTAV-UHFFFAOYSA-N 0.000 claims 1
- WOIQBJLQFNQOKN-UHFFFAOYSA-N 4-(3-methylmorpholin-4-yl)-6-pyrimidin-5-yl-1H-pyridin-2-one Chemical compound CC1N(CCOC1)C1=CC(NC(=C1)C=1C=NC=NC=1)=O WOIQBJLQFNQOKN-UHFFFAOYSA-N 0.000 claims 1
- BLKYINDIAIKVAN-CYBMUJFWSA-N 4-[(3R)-3-methylmorpholin-4-yl]-6-(2-methylphenyl)-1H-pyridin-2-one Chemical compound C[C@H]1N(CCOC1)C1=CC(NC(=C1)C1=C(C=CC=C1)C)=O BLKYINDIAIKVAN-CYBMUJFWSA-N 0.000 claims 1
- ILABODHIHNTFPA-LLVKDONJSA-N 4-[(3R)-3-methylmorpholin-4-yl]-6-(4-methylthiophen-3-yl)-1H-pyridin-2-one Chemical compound C[C@H]1N(CCOC1)C1=CC(NC(=C1)C1=CSC=C1C)=O ILABODHIHNTFPA-LLVKDONJSA-N 0.000 claims 1
- NLODRXAIDDLFIJ-CQSZACIVSA-N 4-[(3R)-3-methylmorpholin-4-yl]-6-(6-methylquinolin-5-yl)-1H-pyridin-2-one Chemical compound C[C@H]1N(CCOC1)C1=CC(NC(=C1)C1=C2C=CC=NC2=CC=C1C)=O NLODRXAIDDLFIJ-CQSZACIVSA-N 0.000 claims 1
- LLOYRXVVALYBAE-LLVKDONJSA-N 4-[(3R)-3-methylmorpholin-4-yl]-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-2-one Chemical compound C[C@H]1N(CCOC1)C1=CC(NC(=C1)C1=C(C=CC=C1)C(F)(F)F)=O LLOYRXVVALYBAE-LLVKDONJSA-N 0.000 claims 1
- NIYLGOFXXWDGHE-SNVBAGLBSA-N 4-[(3R)-3-methylmorpholin-4-yl]-6-[2-(trifluoromethyl)pyridin-3-yl]-1H-pyridin-2-one Chemical compound C[C@H]1N(CCOC1)C1=CC(NC(=C1)C=1C(=NC=CC=1)C(F)(F)F)=O NIYLGOFXXWDGHE-SNVBAGLBSA-N 0.000 claims 1
- WNLMGKKPTNIYAV-CYBMUJFWSA-N 4-[(3R)-3-methylmorpholin-4-yl]-6-[4-(1H-pyrazol-5-yl)phenyl]-1H-pyridin-2-one Chemical compound C[C@H]1N(CCOC1)C1=CC(NC(=C1)C1=CC=C(C=C1)C1=CC=NN1)=O WNLMGKKPTNIYAV-CYBMUJFWSA-N 0.000 claims 1
- FBESKTXSVIMZLT-SNVBAGLBSA-N 6-(2-chloro-5-fluorophenyl)-4-[(3R)-3-methylmorpholin-4-yl]-1H-pyridin-2-one Chemical compound ClC1=C(C=C(C=C1)F)C1=CC(=CC(N1)=O)N1[C@@H](COCC1)C FBESKTXSVIMZLT-SNVBAGLBSA-N 0.000 claims 1
- WYZUZXYELRBYFX-UHFFFAOYSA-N 6-(2-chlorophenyl)-1-methyl-4-(3-methylmorpholin-4-yl)pyridin-2-one Chemical compound ClC1=C(C=CC=C1)C1=CC(=CC(N1C)=O)N1C(COCC1)C WYZUZXYELRBYFX-UHFFFAOYSA-N 0.000 claims 1
- DFACODBEJDPZES-UHFFFAOYSA-N 6-(2-chlorophenyl)-1-methyl-4-morpholin-4-ylpyridin-2-one Chemical compound ClC1=C(C=CC=C1)C1=CC(=CC(N1C)=O)N1CCOCC1 DFACODBEJDPZES-UHFFFAOYSA-N 0.000 claims 1
- CIKYKCUFTCCXHK-UHFFFAOYSA-N 6-(2-chlorophenyl)-4-(3-methylmorpholin-4-yl)-1H-pyridin-2-one Chemical compound ClC1=C(C=CC=C1)C1=CC(=CC(N1)=O)N1C(COCC1)C CIKYKCUFTCCXHK-UHFFFAOYSA-N 0.000 claims 1
- CIKYKCUFTCCXHK-LLVKDONJSA-N 6-(2-chlorophenyl)-4-[(3R)-3-methylmorpholin-4-yl]-1H-pyridin-2-one Chemical compound ClC1=C(C=CC=C1)C1=CC(=CC(N1)=O)N1[C@@H](COCC1)C CIKYKCUFTCCXHK-LLVKDONJSA-N 0.000 claims 1
- KGOYSDHVCLSZMG-UHFFFAOYSA-N 6-(2-chlorophenyl)-4-morpholin-4-yl-1H-pyridin-2-one Chemical compound ClC1=C(C=CC=C1)C1=CC(=CC(N1)=O)N1CCOCC1 KGOYSDHVCLSZMG-UHFFFAOYSA-N 0.000 claims 1
- JSBLNGVJMUICFQ-SNVBAGLBSA-N 6-(furan-3-yl)-4-[(3R)-3-methylmorpholin-4-yl]-1H-pyridin-2-one Chemical compound O1C=C(C=C1)C1=CC(=CC(N1)=O)N1[C@@H](COCC1)C JSBLNGVJMUICFQ-SNVBAGLBSA-N 0.000 claims 1
- 208000004672 Cardiovascular Infections Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- YEZZOSCYOUGCGL-GFCCVEGCSA-N N-[2-[4-[(3R)-3-methylmorpholin-4-yl]-6-oxo-1H-pyridin-2-yl]phenyl]methanesulfonamide Chemical compound C[C@H]1N(CCOC1)C=1C=C(NC(C=1)=O)C1=C(C=CC=C1)NS(=O)(=O)C YEZZOSCYOUGCGL-GFCCVEGCSA-N 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 0 Cc1c(*)ccc(*)c1 Chemical compound Cc1c(*)ccc(*)c1 0.000 description 6
- KJRRQXYWFQKJIP-UHFFFAOYSA-N Cc1c[o]cc1 Chemical compound Cc1c[o]cc1 KJRRQXYWFQKJIP-UHFFFAOYSA-N 0.000 description 1
- TWGNOYAGHYUFFR-UHFFFAOYSA-N Cc1cncnc1 Chemical compound Cc1cncnc1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021199161A JP7389504B2 (ja) | 2016-02-19 | 2021-12-08 | がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物 |
| JP2023192216A JP2024016225A (ja) | 2016-02-19 | 2023-11-10 | がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16156530 | 2016-02-19 | ||
| EP16156530.4 | 2016-02-19 | ||
| PCT/EP2017/053612 WO2017140841A1 (en) | 2016-02-19 | 2017-02-17 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199161A Division JP7389504B2 (ja) | 2016-02-19 | 2021-12-08 | がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505594A JP2019505594A (ja) | 2019-02-28 |
| JP2019505594A5 true JP2019505594A5 (https=) | 2020-03-26 |
| JP6997462B2 JP6997462B2 (ja) | 2022-01-17 |
Family
ID=55404645
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562701A Active JP6997462B2 (ja) | 2016-02-19 | 2017-02-17 | がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物 |
| JP2021199161A Active JP7389504B2 (ja) | 2016-02-19 | 2021-12-08 | がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物 |
| JP2023192216A Pending JP2024016225A (ja) | 2016-02-19 | 2023-11-10 | がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199161A Active JP7389504B2 (ja) | 2016-02-19 | 2021-12-08 | がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物 |
| JP2023192216A Pending JP2024016225A (ja) | 2016-02-19 | 2023-11-10 | がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11077113B2 (https=) |
| EP (1) | EP3416945B1 (https=) |
| JP (3) | JP6997462B2 (https=) |
| CN (3) | CN113845472A (https=) |
| AU (3) | AU2017219846B2 (https=) |
| CY (1) | CY1123285T1 (https=) |
| DK (1) | DK3416945T3 (https=) |
| ES (1) | ES2816376T3 (https=) |
| HR (1) | HRP20201400T1 (https=) |
| HU (1) | HUE050863T2 (https=) |
| LT (1) | LT3416945T (https=) |
| PL (1) | PL3416945T3 (https=) |
| PT (1) | PT3416945T (https=) |
| RS (1) | RS60898B1 (https=) |
| RU (1) | RU2754664C2 (https=) |
| SI (1) | SI3416945T1 (https=) |
| SM (1) | SMT202000523T1 (https=) |
| TW (1) | TWI721104B (https=) |
| WO (1) | WO2017140841A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3416957T3 (da) * | 2016-02-19 | 2020-09-21 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes |
| AU2017219846B2 (en) * | 2016-02-19 | 2021-05-13 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
| JP7199738B2 (ja) | 2017-08-23 | 2023-01-06 | スプリント バイオサイエンス アクティエボラーグ | アザインドリルピリドンおよびジアザインドリルピリドン化合物 |
| WO2019038387A1 (en) | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | PYRIDYLPYRIDONE COMPOUNDS |
| US11560374B2 (en) * | 2017-08-23 | 2023-01-24 | Sprint Bioscience Ab | Morpholinylpyridone compounds |
| CN111094271B (zh) | 2017-08-23 | 2023-02-28 | 思普瑞特生物科学公司 | 吡啶胺-吡啶酮化合物和嘧啶胺-吡啶酮化合物 |
| WO2020008046A1 (en) | 2018-07-06 | 2020-01-09 | Sprint Bioscience Ab | Biomarker |
| WO2021035031A1 (en) * | 2019-08-21 | 2021-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
| CA3199988A1 (en) | 2020-11-25 | 2022-06-02 | Daniel L. Flynn | Pyridylpyridone derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
| CA3200003A1 (en) * | 2020-11-25 | 2022-06-02 | Daniel L. Flynn | Anti-viral activity of vps34 inhibitors |
| WO2022115562A1 (en) | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7423148B2 (en) | 2002-11-21 | 2008-09-09 | Chiron Corporation | Small molecule PI 3-kinase inhibitors and methods of their use |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| BRPI1015943A8 (pt) | 2009-07-02 | 2018-01-09 | Sanofi Sa | derivados de 1,2,3,4-tetra - hidro - pirimido {1,2-a} pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica. |
| AU2011346567A1 (en) | 2010-12-21 | 2013-07-25 | Novartis Ag | Bi-heteroaryl compounds as Vps34 inhibitors |
| DK2655375T3 (en) | 2010-12-23 | 2015-03-09 | Sanofi Sa | PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014145512A2 (en) * | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Potent small molecule inhibitors of autophagy, and methods of use thereof |
| JP6074043B2 (ja) * | 2013-08-29 | 2017-02-01 | 富士フイルム株式会社 | 新規なモルホリン誘導体またはその塩 |
| AU2015206652A1 (en) | 2014-01-14 | 2016-08-04 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| US10189810B2 (en) * | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| AU2017219846B2 (en) * | 2016-02-19 | 2021-05-13 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
-
2017
- 2017-02-17 AU AU2017219846A patent/AU2017219846B2/en active Active
- 2017-02-17 HR HRP20201400TT patent/HRP20201400T1/hr unknown
- 2017-02-17 RU RU2018131775A patent/RU2754664C2/ru active
- 2017-02-17 US US15/999,530 patent/US11077113B2/en active Active
- 2017-02-17 PT PT177058781T patent/PT3416945T/pt unknown
- 2017-02-17 SM SM20200523T patent/SMT202000523T1/it unknown
- 2017-02-17 CN CN202111123598.XA patent/CN113845472A/zh active Pending
- 2017-02-17 CN CN202111121825.5A patent/CN113754581A/zh active Pending
- 2017-02-17 WO PCT/EP2017/053612 patent/WO2017140841A1/en not_active Ceased
- 2017-02-17 DK DK17705878.1T patent/DK3416945T3/da active
- 2017-02-17 LT LTEP17705878.1T patent/LT3416945T/lt unknown
- 2017-02-17 PL PL17705878T patent/PL3416945T3/pl unknown
- 2017-02-17 SI SI201730395T patent/SI3416945T1/sl unknown
- 2017-02-17 RS RS20201057A patent/RS60898B1/sr unknown
- 2017-02-17 JP JP2018562701A patent/JP6997462B2/ja active Active
- 2017-02-17 TW TW106105179A patent/TWI721104B/zh not_active IP Right Cessation
- 2017-02-17 CN CN201780013738.3A patent/CN108698996B/zh active Active
- 2017-02-17 HU HUE17705878A patent/HUE050863T2/hu unknown
- 2017-02-17 EP EP17705878.1A patent/EP3416945B1/en active Active
- 2017-02-17 ES ES17705878T patent/ES2816376T3/es active Active
-
2020
- 2020-08-27 CY CY20201100804T patent/CY1123285T1/el unknown
-
2021
- 2021-06-29 US US17/362,763 patent/US11633403B2/en active Active
- 2021-08-12 AU AU2021215234A patent/AU2021215234B2/en not_active Ceased
- 2021-12-08 JP JP2021199161A patent/JP7389504B2/ja active Active
-
2023
- 2023-03-09 US US18/181,046 patent/US20240050439A1/en not_active Abandoned
- 2023-10-13 AU AU2023248170A patent/AU2023248170A1/en not_active Abandoned
- 2023-11-10 JP JP2023192216A patent/JP2024016225A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505594A5 (https=) | ||
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| TWI671297B (zh) | 治療癌症及非腫瘤病症之方法 | |
| JP6952695B2 (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| KR102001745B1 (ko) | 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물 | |
| AU2012382875B2 (en) | Compound as WNT signaling inhibitor, composition, and use thereof | |
| CN106132950B (zh) | 氨基吡啶类化合物和使用方法 | |
| TWI535442B (zh) | A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine | |
| CN113474347A (zh) | Mat2a的aza杂双环抑制剂和用于治疗癌症的方法 | |
| JP2019505595A5 (https=) | ||
| JP2019527731A (ja) | Ｈｂｖ感染の治療のための新規治療薬 | |
| JP7201260B2 (ja) | ピリジンアミン－ピリドンおよびピリミジンアミン－ピリドン化合物 | |
| AU2019378184A1 (en) | 2,3-dihydro-1H-pyrrolo(3,4-c)pyridin-1-one derivatives as HPK1 inhibitors for the treatment of cancer | |
| CA2926478A1 (en) | Rho kinase inhibitors | |
| JP2016514719A5 (https=) | ||
| JP2013500311A (ja) | タンパク質キナーゼ調節剤としてのピリジンおよびピラジン誘導体 | |
| JP2012506381A5 (https=) | ||
| JP2015512896A (ja) | 新規なピリドピリミジン誘導体及びその用途 | |
| JP2009526072A5 (https=) | ||
| JP2016528298A5 (https=) | ||
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| TW202003507A (zh) | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 | |
| KR20190092545A (ko) | 인플루엔자 바이러스 복제의 억제제 및 이의 용도 | |
| JP2018535931A (ja) | 二重ＤＹＲＫ１／ＣＬＫ１阻害剤としての新規イミダゾ［４，５−ｂ］ピリジン誘導体 | |
| CN110117285B (zh) | 流感病毒复制抑制剂及其用途 |